Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

433.07
-20.6700-4.56%
Post-market: 433.300.2300+0.05%19:49 EDT
Volume:1.92M
Turnover:837.06M
Market Cap:109.88B
PE:28.27
High:452.00
Open:450.95
Low:431.01
Close:453.74
52wk High:510.77
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.38
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:5.89
PE(LYR):28.27

Loading ...

Vertex Minerals Reports Final Sales Revenue of Over AU$300,000 for December 2025; Shares Down 4%

MT Newswires Live
·
Jan 16

Vertex Minerals Lifts Output at Reward Gold Mine as Higher-Grade Ore Flows Underground

TIPRANKS
·
Jan 16

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 14

TD Cowen Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jan 13

Bernstein Upgrades Vertex Pharmaceuticals to Outperform From Market Perform

MT Newswires Live
·
Jan 12

Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein

TIPRANKS
·
Jan 12

Vertex Pharmaceuticals Announces Pipeline Progress and 2026 Milestones

Reuters
·
Jan 12

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jan 10

Vertex Pharmaceuticals EVP Ourania Tatsis Reports Sale of Common Shares

Reuters
·
Jan 10

Vertex Pharmaceuticals EVP, CO & FO Charles F. Wagner Jr. Reports Disposal of Common Shares

Reuters
·
Jan 09

Vertex Pharmaceuticals (VRTX) Is Up 6.8% After IgA Nephropathy Outlook Upgrade - Has The Bull Case Changed?

Simply Wall St.
·
Jan 09

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $625 From $604, Maintains Buy Rating

MT Newswires Live
·
Jan 09

Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story

TIPRANKS
·
Jan 09

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jan 08

UBS Adjusts Price Target on Vertex Pharmaceuticals to $535 From $546, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Vertex Pharmaceuticals Coverage Assumed by UBS at Buy

Dow Jones
·
Jan 07

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jan 07